Elise McPherson, DO
Internal Medicine · Dubuque, IANPI 1326532425
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Pfizer at 24.9% of the total. 2025 is the largest year on record at $1,020, more than ten times the $18 reported in 2019. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$443
- AbbVie$260
- Novo Nordisk$157
- Amgen$89
- Harmony Biosciences LLC$82
- AstraZeneca$81
- plus $669 from 18 others
What the payments were for
- Food & beverage$1,781100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 24 | $443 |
| AbbVie | 16 | $260 |
| Novo Nordisk | 9 | $157 |
| Amgen | 6 | $89 |
| Harmony Biosciences LLC | 1 | $82 |
| AstraZeneca | 5 | $81 |
| Lilly USA, LLC | 5 | $80 |
| Astellas Pharma US Inc | 4 | $74 |
| Johnson & Johnson | 3 | $69 |
| Bayer | 4 | $62 |
| Exact Sciences | 3 | $58 |
| Boehringer Ingelheim | 4 | $57 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Mylan Specialty L.p. | 2 | $35 |
| Lundbeck LLC | 2 | $35 |
| Dexcom, Inc. | 2 | $33 |
| Novartis | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $18 |
| Stryker | 1 | $17 |
| GSK | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Celltrion USA Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$125
How this compares
$1,781 in reported general payments places this provider in the 90th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 13 | $95,776 |
| EliquisApixaban | 85 | $61,688 |
| MounjaroTirzepatide | 41 | $54,620 |
| OzempicSemaglutide | 35 | $42,811 |
| RybelsusSemaglutide | 39 | $42,673 |
| FarxigaDapagliflozin Propanediol | 71 | $37,789 |
| JardianceEmpagliflozin | 36 | $34,522 |
| XareltoRivaroxaban | 30 | $19,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $17,203 |
| JanuviaSitagliptin Phosphate | 27 | $12,114 |
| InvokanaCanagliflozin | 14 | $10,448 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,220 |
| Atrovent HfaIpratropium Bromide | 17 | $7,893 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $6,693 |
| Midodrine Hcl | 15 | $4,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $157 | $85,48474 claims |
| PfizerEliquis | $443 | $61,68885 claims |
| Lilly USA, LLCMounjaro | $80 | $54,62041 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $57 | $43,74254 claims |
| AstraZenecaFarxiga | $81 | $37,78971 claims |
| Johnson & JohnsonXarelto, Invokana | $69 | $30,26944 claims |
| GSKTrelegy Ellipta | $16 | $17,20322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Dubuque
- Hillard SalasDubuque$2K
- Zhengjin CaoDubuque$2K
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.